Ziping Qi

1.5k citations

32 papers · 891 · 1 hit paper · h-index 14

Impact in

Molecular Biology
- Heat shock proteins research
- Cancer therapeutics and mechanisms
- Protein Degradation and Inhibitors
Aging

Papers in

Molecular Biology 13
- PI3K/AKT/mTOR signaling in cancer 4
Hematology 10
- Chronic Myeloid Leukemia Treatments 6
- Platelet Disorders and Treatments 3

Co-authors: Jing Liu (24 shared papers)Qingsong Liu (21 shared papers)Fengming Zou (17 shared papers)Wenchao Wang (11 shared papers)Chen Hu (5 shared papers)Beilei Wang (7 shared papers)Jing Yang (1 shared paper)Husheng Mei (1 shared paper)
Journals: Journal of Medicinal Chemistry (10 papers)European Journal of Medicinal Chemistry (4 papers)Signal Transduction and Targeted Therapy (2 papers)Acta Pharmacologica Sinica (2 papers)ACS Chemical Biology (1 paper)
Partner nations: China United States

In The Last Decade

Ziping Qi

31 papers receiving 881 citations

Ziping Qi's Hit Papers

align trajectories log scale

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities 2022 · 459 citations

Peers

Countries citing papers authored by Ziping Qi

Since Specialization

Citations

This map shows the geographic impact of Ziping Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziping Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziping Qi more than expected).

Fields of papers citing papers by Ziping Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ziping Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziping Qi. The network helps show where Ziping Qi may publish in the future.

Co-authors

The 25 scholars most cited alongside Ziping Qi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ziping Qi Line = papers co-authored together Ziping Qi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities MedComm ·Chen Hu, Jing Yang, Ziping Qi, Hong Wu, Beilei Wang, Fengming Zou, Husheng Mei, Jing Liu, Wenchao Wang, Qingsong Liu Hit paper breakdown →	2022	459
2	Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC European Journal of Medicinal Chemistry ·Yongfei Chen, Jiaxin Wu, Aoli Wang, Ziping Qi, Taoshan Jiang, Chen Cheng, Fengming Zou, Chen Hu, Wei Wang, Wu Hong, Zhenquan Hu, Wenchao Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Qingsong Liu, Jing Liu	2017	55
3	Magnetosome-inspired synthesis of soft ferrimagnetic nanoparticles for magnetic tumor targeting Proceedings of the National Academy of Sciences ·Kun Ma, Shuai Xu, Tongxiang Tao, Junchao Qian, Qiqi Cui, Sajid Ur Rehman, Xiaoguang Zhu, Ruiguo Chen, Hongxin Zhao, Changhao Wang, Ziping Qi, Han Dai, Xin Zhang, Can Xie, Yang Lü, Hongzhi Wang, Junfeng Wang	2022	39
4	Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent Acta Pharmaceutica Sinica B ·Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu	2019	30
5	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode Journal of Medicinal Chemistry ·Aoli Wang, Xixiang Li, Hong Wu, Fengming Zou, Xiao-E Yan, Chen Cheng, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai‐Hong Yun, Jing Liu, Qingsong Liu	2017	28
6	Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway Acta Pharmacologica Sinica ·Cheng Chen, Chuan-dong Cheng, Hong Wu, Zuowei Wang, Li Wang, Zongru Jiang, Aoli Wang, Chen Hu, Yongfei Dong, Wanxiang Niu, Shuang Qi, Ziping Qi, Jing Liu, Wenchao Wang, Chaoshi Niu, Qingsong Liu	2020	26
7	Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia Journal of Medicinal Chemistry ·Xixiang Li, Aoli Wang, Kailin Yu, Ziping Qi, Cheng Chen, Wenchao Wang, Hu Chen, Wu Hong, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Lı Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu, Qingsong Liu	2015	26
8	Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode Oncotarget ·Chen Hu, Aoli Wang, Hong Wu, Ziping Qi, Xixiang Li, Xiao-E Yan, Chen Cheng, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai‐Hong Yun, Jing Liu, Qingsong Liu	2017	17
9	Discovery of 6′-chloro-N-methyl-5’-(phenylsulfonamido)-[3,3′-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium European Journal of Medicinal Chemistry ·Xiaofei Liang, Zongru Jiang, Zhenghui Huang, Feng Li, Cheng Chen, Chen Hu, Wenliang Wang, Zhenquan Hu, Qingwang Liu, Beilei Wang, Li Wang, Ziping Qi, Jing Liu, Lubin Jiang, Qingsong Liu	2019	16
10	Discovery of (E)-N¹-(3-Fluorophenyl)-N³-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs) Journal of Medicinal Chemistry ·Xuesong Liu, Beilei Wang, Cheng Chen, Ziping Qi, Fengming Zou, Jun‐Jie Wang, Chen Hu, Aoli Wang, Juan Ge, Qingwang Liu, Kailin Yu, Zhenquan Hu, Zongru Jiang, Wei Wang, Li Wang, Wenchao Wang, Tao Ren, Mingfeng Bai, Qingsong Liu, Jing Liu	2019	16
11	Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia European Journal of Medicinal Chemistry ·Qiang Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Xiao-E Yan, Beilei Wang, Aoli Wang, Wei Wang, Chen Cheng, Xiaochuan Liu, Zongru Jiang, Zhenquan Hu, Li Wang, Wenchao Wang, Tao Ren, Shanchun Zhang, Cai‐Hong Yun, Qingsong Liu, Jing Liu	2018	15
12	Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia Journal of Medicinal Chemistry ·Xiaofei Liang, Xiaochuan Liu, Beilei Wang, Fengming Zou, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu, Jing Liu	2016	14
13	Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus Signal Transduction and Targeted Therapy ·Junjie Wang, Ziping Qi, Yun Wu, Aoli Wang, Qingwang Liu, Fengming Zou, Beilei Wang, Shuang Qi, Jiangyan Cao, Hu Chen, Chenliang Shi, Qianmao Liang, Li Wang, Jing Liu, Wenchao Wang, Qingsong Liu	2023	14
14	Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors Journal of Medicinal Chemistry ·Yun Wu, Beilei Wang, Junjie Wang, Shuang Qi, Fengming Zou, Ziping Qi, Feiyang Liu, Qingwang Liu, Cheng Chen, Chen Hu, Zhenquan Hu, Aoli Wang, Li Wang, Wenchao Wang, Tao Ren, Yujiao Cai, Mingfeng Bai, Qingsong Liu, Jing Liu	2019	13
15	Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models Cancer Letters ·Tingting Lu, Cheng Chen, Aoli Wang, Zongru Jiang, Ziping Qi, Zhenquan Hu, Chen Hu, Feiyang Liu, Wenliang Wang, Wu Hong, Beilei Wang, Li Wang, Shuang Qi, Jiaxin Wu, Wenchao Wang, Jun Tang, Hezhong Yan, Mingfeng Bai, Qingsong Liu, Jing Liu	2019	12
16	Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding Journal of Medicinal Chemistry ·Qiang Wang, Feiyang Liu, Beilei Wang, Fengming Zou, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu, Jing Liu	2016	12
17	Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Journal of Medicinal Chemistry ·Feng Li, Xiaofei Liang, Zongru Jiang, Aoli Wang, Junjie Wang, Cheng Chen, Wenliang Wang, Fengming Zou, Ziping Qi, Qingwang Liu, Zhenquan Hu, Jiangyan Cao, Hong Wu, Beilei Wang, Li Wang, Jing Liu, (unknown), (unknown)	2020	12
18	Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models Investigational New Drugs ·Li Wang, Chen Hu, Aoli Wang, Cheng Chen, Jiaxin Wu, Zongru Jiang, Fengming Zou, Kailin Yu, Hong Wu, Juan Liu, Wenliang Wang, Zuowei Wang, Beilei Wang, Ziping Qi, Qingwang Liu, Wenchao Wang, Lili Li, Jian Ge, Jing Liu, Qingsong Liu	2019	11
19	Effects of 3.7 T–24.5 T high magnetic fields on tumor-bearing mice Chinese Physics B ·Xiaofei Tian, Ze Wang, Lei Zhang, Chuanying Xi, Li Pi, Ziping Qi, Qingyou Lu, Xin Zhang	2018	10
20	Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes Journal of Medicinal Chemistry ·Yun Wu, Ziping Qi, Beilei Wang, Jun‐Jie Wang, Qingwang Liu, Aoli Wang, Chenliang Shi, Bin Zhou, Qianmao Liang, Wenliang Wang, Fengming Zou, Shuang Qi, Zuowei Wang, Li Wang, Wenchao Wang, Jing Liu, Qingsong Liu	2022	9

About Ziping Qi

Ziping Qi is a scholar working on Molecular Biology, Hematology, Pulmonary and Respiratory Medicine, Oncology and Immunology, having authored 32 papers that have together received 891 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Gastrointestinal Tumor Research and Treatment (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Quinazolinone synthesis and applications (3 papers), Immune Cell Function and Interaction (3 papers), HER2/EGFR in Cancer Research (3 papers) and Platelet Disorders and Treatments (3 papers). The work is most often cited by research in Molecular Biology (440 citations), Aging (10 citations), Cell Biology (77 citations), Gastroenterology (23 citations) and Genetics (44 citations). Ziping Qi has collaborated with scholars based in China and United States. Frequent co-authors include Jing Liu, Qingsong Liu, Fengming Zou, Wenchao Wang, Chen Hu, Beilei Wang, Jing Yang, Husheng Mei, Aoli Wang and Beilei Wang. Their work appears in journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Signal Transduction and Targeted Therapy, Acta Pharmacologica Sinica and ACS Chemical Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ziping Qi

Impact in

Papers in i

In The Last Decade

Ziping Qi

Ziping Qi's Hit Papers

Peers

Countries citing papers authored by Ziping Qi

Fields of papers citing papers by Ziping Qi

All Works

About Ziping Qi

Explore authors with similar magnitude of impact

Papers in